The utilization of ICIs is quite significant for this malignancy, especially for the tumors that are dMMR/MSI-H, in comparison with proficient MMR (pMMR) or microsatellite-stable (MSS) in which the response to ICIs is unfavorable [ 139 ].
← all excerpts
Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.
1
—
—